Top Markets
#1 Pons Pons +55.25%
#2 Purr Purr +54.08%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Non-Playable Coin Non-Playable Coin +34.40%
#5 TENDIES TENDIES +28.49%
#6 Cash Cat Cash Cat +27.00%
#7 Morpho Morpho +24.89%
#8 Kinetiq Kinetiq +24.27%
#9 StonkBroker StonkBroker +22.49%
#10 ApeX ApeX +22.18%
Coin of the day
Pons Pons
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Peringkat dalam Saham #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Harga Saham
$1.54
Terakhir disinkronkan: 2024-04-08
Kapitalisasi Pasar
$119.21M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan NGM Biopharmaceuticals, Inc. (NGM)

Kategori

Healthcare
Riwayat hasil dividen untuk NGM Biopharmaceuticals, Inc. (NGM)
Hasil dividen (TTM) dari NGM Biopharmaceuticals, Inc. (simbol saham: NGM) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk NGM Biopharmaceuticals, Inc. (NGM) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
Perusahaan Hasil Dividen Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH